A new secondary analysis followed adults who were beginning to use retail cannabis edibles for chronic low back pain. On days when people in the THC-dominant and THC-plus-CBD groups used their products, they reported less pain than on their own non-use days. Across two weeks, however, only the group using products with relatively comparable amounts of THC and CBD showed a statistically significant downward trend.
The study was preregistered and collected daily data, but participants selected their own products, knew what they were taking, and had no randomized placebo comparison. It can describe what happened during natural use; it cannot establish treatment efficacy.
What the Researchers Did
The study, published July 21 in Biomedicines, used previously unreported daily surveys from a larger University of Colorado Boulder project. The parent trial was preregistered as NCT03522324. Participants were 21 to 70 years old, had experienced low back pain for at least three months, and intended to begin cannabis use for that pain.
Instead of assigning a standardized study drug, researchers gave participants information about locally available edibles and public-health guidance. Participants then bought a product from a Colorado recreational dispensary, chose how often to use it, and were asked not to use other cannabis products during the study. Researchers classified the products using the THC and CBD amounts printed on their labels.
That naturalistic approach is the study's practical strength: it resembles how adults actually choose and use legal-market edibles. It is also the central limitation. People who picked a CBD-dominant product differed from those who picked a THC-dominant one, and everyone knew the product's cannabinoid content. The models adjusted for several measured differences and for participants' expectations about cannabis and pain, but statistical adjustment cannot remove every source of selection, expectation, or confounding.
The Main Findings, Without the Hype
| Comparison | What the study found | How to read it |
|---|---|---|
| Use days vs. non-use days | Estimated pain was 17.0% lower in the THC-dominant group and 9.9% lower in the THC+CBD group on use days. The 1.9% difference in the CBD-dominant group was not statistically significant. | The THC-containing groups showed an association within participants. This was not a placebo-controlled treatment effect. |
| Day 1 vs. day 14 | Only the THC+CBD group had a statistically significant decline over time, with estimated average pain 14.4% lower on day 14. | The average change was modest and below the study's cited 30% threshold for a moderately meaningful improvement. |
| Meaningful individual response | 36.6% of the THC+CBD group reported at least a 30% reduction from day 1 to day 14, compared with 26.8% in the CBD-dominant group and 26.5% in the THC-dominant group. | Without placebo or randomization, those percentages cannot tell us how many responses were caused by the products. |
| Dose models | More THC was associated with higher pain on the same day but lower pain the following day when modeled at zero CBD. CBD dose alone was not associated with lower pain. | People may have taken more THC when pain was worse. The lagged finding is exploratory and does not establish an optimal dose. |
Statistically Significant Is Not the Same as Dramatic Relief
The researchers explicitly addressed clinical importance. The average same-day differences for the THC-containing groups were about 10% to 17%, and the two-week change in the THC+CBD group was about 14%. The authors categorized changes in that range as minimally important, not moderately meaningful. That distinction is easy to lose when a headline reports only that pain “significantly decreased.”
The 36.6% responder figure in the THC+CBD group is worth testing in a randomized trial. It should not be presented as a response rate consumers can expect. Pain naturally fluctuates, people may feel better because they expect to, and regression toward the mean can make symptoms improve after someone enrolls while feeling unusually bad. A control group is what helps separate those effects from a product effect.
The THC-CBD Interaction Is Interesting—and Easy to Misuse
In the exploratory dose analysis, higher THC dose was associated with lower pain the following day, while greater CBD dose weakened that statistical association. The authors discuss a possible receptor-level explanation, but they also say the dose findings require caution. Doses were self-reported, product potency came from labels, and commercial edible labels may not always match laboratory measurement.
This is not evidence that consumers should avoid CBD, increase THC, or copy a specific ratio. The three product groups were unbalanced, the THC-dominant group was the smallest, and dose was not randomly assigned. Same-day data even moved in the opposite direction: higher THC was associated with higher current pain, plausibly because participants took more when they hurt more. Only a controlled dose-ranging trial can sort out direction, ratio, benefit, and harm.
How This Fits the Larger Chronic Pain Evidence
The study adds real-world data in a condition where controlled evidence remains thin. The final 2025 AHRQ living systematic review found that some comparable THC-to-CBD and high-THC products produced small short-term pain improvements, mainly in neuropathic pain studies. It also found increased dizziness, sedation, and nausea for some formulations. Evidence for whole-plant products, many common pain conditions, longer-term outcomes, and important harms remained limited or insufficient.
Those randomized trials and this observational edible study answer different questions. Trials are stronger for cause and effect but often use standardized medicines that do not resemble dispensary products. Naturalistic studies show what happens with products people actually choose, but they leave more competing explanations. CannaWize's full chronic pain evidence review puts the product-specific benefits and harms in context.
What the Study Cannot Tell Patients
- Whether an edible caused the observed pain change.
- Whether the result would last beyond 14 days or improve function, sleep, work, or quality of life.
- Which dose or THC-to-CBD ratio offers the best balance of benefit and adverse effects.
- Whether the findings apply to older adults, more diverse populations, specific back-pain diagnoses, or people who use cannabis regularly.
- How the edibles compare with physical therapy, non-cannabis medication, usual care, or placebo.
The sample was mostly White and well educated, chronic low back pain was self-reported rather than separated by diagnosis, and the observation period was short. The analysis also focused on pain intensity; it was not designed to establish the comparative safety of the chosen products.
A Practical Safety Reading
Edibles take longer to produce noticeable effects than inhaled cannabis and may remain active longer, which can make early redosing risky. THC can impair driving, balance, judgment, and reaction time. CBD and THC can also interact with medications. The FDA notes unresolved safety questions and interaction risks for widely sold cannabis-derived products.
Someone considering cannabis for persistent back pain should start with the diagnosis and treatment plan, not a headline about cannabinoid ratio. New weakness, bowel or bladder changes, saddle numbness, fever, major trauma, unexplained weight loss, or rapidly worsening pain warrants prompt medical evaluation. For an ongoing cannabis conversation, bring the exact product, label, serving size, medication list, and goals to a clinician or pharmacist. CannaWize's medication-interaction checklist and driving research guide cover two of the most practical risk areas.
The Bottom Line
This study found a credible signal worth following: during 14 days of self-directed use, THC-containing edibles were associated with modestly lower daily pain, and the THC+CBD group showed the clearest change across time. It did not prove that retail edibles treat chronic low back pain, identify a best dose, or show that adding or removing CBD will improve an individual's result.
The next useful study is not another product survey. It is a randomized, blinded trial that verifies cannabinoid content, compares specific doses and ratios, measures function and adverse effects, and follows participants long enough to evaluate tolerance and sustained benefit.
Clear answers
Frequently Asked Questions
Did this study prove that cannabis edibles treat chronic low back pain?
No. The study found associations between THC-containing edible use and lower self-reported pain, but participants chose their own products and there was no random assignment or placebo group.
Which products were associated with lower pain in the study?
THC-dominant and THC-plus-CBD products were associated with lower pain on use days. Only the THC-plus-CBD group showed a statistically significant decline in average pain across the 14-day observation period.
Did CBD-dominant edibles reduce pain in the study?
CBD-dominant products were not associated with statistically significant daily or 14-day pain reductions in this study. That result applies to the products, doses, population, and short duration observed; it does not settle every question about CBD and pain.